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Acute renal failure: From renal physiology to the renal tran-
scriptome. Acute renal failure (ARF) is defined as an abrupt
fall in glomerular filtration rate. Fully 5% of all patients admit-
ted to the hospital undergo ARF with an attendant increase
in morbidity and mortality. We have studied murine models of
ischemia/reperfusion and cisplatin-induced renal failure in de-
tail to determine the physiologic and molecular events that are
responsible for the syndrome. Both forms of treatment induce
necrosis of the proximal tubules, as well as more subtle changes
in distal nephron viability, including apoptosis. Both forms are
characterized by reduced renal blood, reduced glomerular fil-
tration rate, and a urine-concentrating defect. Simultaneous
with the onset of these morphologic and functional features
is the commitment of cells to DNA synthesis and cell division,
which is preceded by activation of signal transduction pathways
and gene transcription that presumably underlie the morpho-
logic and functional changes responsible for the syndrome. We
describe a functional genomic approach using microarray data
and available database searches to attempt to predict new tar-
gets for investigation of the pathogenesis and treatment of this
disease.
PHYSIOLOGIC HALLMARKS OF ACUTE
RENAL FAILURE
Ischemia/reperfusion and cisplatin predictably lower
glomerular filtration rate (GFR), the latter in a clear dose-
dependent manner [1] after a single drug exposure. Early
proteinuria is mild (<500 mg/day), as is glycosuria. In a
few patients, significant urinary electrolyte wasting may
be provoked by cisplatin [2], including severe sodium, di-
valent action, and phosphate wasting, seen primarily with
high-dose therapy. Most common is the gradual onset of
nonoliguric renal failure, with an accompanying defect in
concentrating ability (Fig. 1) [3]. In micropuncture exper-
iments, the site of altered water reabsorption is beyond
the late distal tubule, probably in the apparently morpho-
logically intact collecting duct [3]. In rats, the cause of the
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fall in glomerular filtration is afferent vasoconstriction
and possibly an altered ultrafiltration coefficient before
evidence of tubule obstruction [1]. The precise patho-
genesis for these changes in segmental water transport
and vascular resistance remains unknown, but molecular
studies are beginning to yield insights into these events
(see below).
MORPHOLOGY OF ARF
At least three cellular fates can be identified in acute
renal failure (ARF): cells may die either by frank necro-
sis or by apoptosis; they may replicate and divide; or they
may appear indifferent to the stress (Fig. 2). Frank necro-
sis, as is often seen experimentally, is not prominent in the
vast majority of human cases. Necrosis is usually patchy,
involving individual cells or small clusters of cells, some-
times resulting in small areas of denuded basement mem-
brane. Less obvious injury is more often noted, including
loss of brush borders, flattening of the epithelium, detach-
ment of cells, intratubular cast formation, and dilatation
of the lumen. Although proximal tubules show many of
theses changes, injury to the distal nephron can also be
demonstrated when human biopsy material is closely ex-
amined, but experimentally, the thick ascending limb is
spared from necrosis.
Apoptosis has been noted in ischemic and nephrotoxic
forms of ARF. This form of cell death differs from frank
necrosis in that it requires the activation of a regulated
program that leads to DNA fragmentation, cytoplasmic
condensation, and cell loss without precipitating an in-
flammatory response. In contradistinction to necrosis, the
principal site of apoptotic cell death is the distal nephron.
THE RENAL STRESS RESPONSE
Cellular stress, including that induced by oxidants and
DNA-damaging agents similar to cisplatin, activates two
related parts of the mitogen-activated protein kinase sig-
naling pathway, or MAPKs—the extracellular-regulated
protein kinases, or ERKs, and the stress-activated
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Fig. 1. Maximum concentrating ability in control and cisplatin (CDDP)-treated animals following a 24-hour period of water depreviation and 1000
mU of ADH.
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Fig. 2. Radiohistogram of outer stripe of outer medulla of rat kidney
taken from animal 5 days after cisplatin 5mg/kg BW. Note three cell
fates: necrosis (ND) of cells lining injured S3 segment; apparent indif-
ference of thick ascending limb (TAL) and collecting duct (CD) epithe-
lial cells; cells of the proximal tubule (PT) undergoing DNA synthesis
(arrow). Condensed nuclear debris may also be seen in such section
indicating apoptotic bodies (not shown).
protein kinase (SAPK), also know as Jun N-terminal ki-
nase (JNK) [4]. A balance between the activation of the
ERKs and the SAPKs seems to exist in determining cell
fate during the stress applied by ischemia/reperfusion.
Observations in vivo revealed activation of ERK was
restricted to surviving thick ascending limb cells during
ischemia/reperfusion, while JNK activation was demon-
strated in both proximal and distal tubule cells [5].
Furthermore, inhibition of JNK in vivo ameliorated
ischemic/reperfusion–induced ARF [6]. By manipulating
the balance between ERK and JNK, we showed that oxi-
dant injury–induced necrosis could be ameliorated by ei-
ther up-regulation of endogenous ERK, or inhibition of
JNK [7]. These studies confirmed the crucial role played
by the MAPK pathway in determining outcome.
CELL CYCLE EVENTS IN ACUTE RENAL
FAILURE
The kidney also commits to DNA synthesis rapidly
after injury, and the commitment coincides temporally
with the emergence of the morphologic and functional
derangements of ARF. The rapid appearance of mRNA
for the “immediate-early” genes including proliferating
cell nuclear antigen (PCNA), mark the commitment to
the cell cycle [10].
However, coincident with this increased activity, we
have shown that the p21WAF1/CIP1/SDI1 gene is activated
in murine kidney cells in all experimental models of ARF
[10]. This protein binds to and inhibits cyclin-dependent
protein kinases, whose cyclic oscillations coincide with
the progression of cells through consecutive stages of the
cell cycle. The sites of p21 mRNA over-expression were
localized by in situ hybridization to the cells of the thick
ascending limbs and distal convoluted tubule cells in the
cortex that do not participate in the DNA synthetic re-
sponse to ARF. Experiments in mice whose p21 gene has
been knocked out demonstrate a protective role of the
p21 gene product in ARF [10].
MOLECULAR RESPONSES TO RENAL INJURY
The MAPK pathway activates and represses gene
expression by phosphorylating constitutively expressed
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Fig. 3. Northern analysis of kidney c-fos and c-jun mRNA in control
and cisplatin-induced acute renal failure.
transcription factors. These include the activator protein-
1 (AP-1) transcription factor components, c-fos and
c-Jun. These factors in combination with other factors
activate and repress large groups of genes in response
to cellular stress [8]. We found that prominent members
of these stress-related genes were activated following
ischemia- or cisplatin-induced ARF (Fig. 3). Inhibition
of new protein synthesis superinduced these genes dur-
ing ischemia, proving that, like other situations of stress,
the kidney is able to mount a typical immediate early
gene response. Other immediate early genes were acti-
vated in the kidney as a consequence of ischemia and
cisplatin, including the chemokines interleukin-8 (IL-
8) and monocyte chemoattractant protein-1 (MCP-1),
which are potent leukocyte chemotactic agents [8]. Sub-
sequently increased expression of several cytokines and
chemokines has been demonstrated in various mod-
els of ARF, including tumor necrosis factor-a (TNF-a),
transforming growth factor-b (TGF-b), RANTES, and
MIP-2 [9], some of which were found to play impor-
tant roles in the pathogenesis of ARF. Thus, the kidney
expresses a stress response, including activation of the
MAPKs and subsequent activation of proto-oncogene
and chemokines, which are crucial to the outcome of
ischemia- and cisplatin-induced ARF.
ANALYSIS OF THE RENAL TRANSCRIPTOSOME
DURING CISPLATIN-INDUCED ACUTE RENAL
FAILURE
Given the complex nature of the reaction of the kidney
to injury, including differences in segment-specific cell
fate and altered renal function, and the observation that
activation of signal transduction and differential gene
regulation occurs well before obvious changes in renal
function and morphology take place, we adopted the use
of gene microarrays to analyze changes in the renal tran-
scriptosome more broadly over time. We used the model
of cisplatin-induced renal failure because unlike the renal
ischemia/reperfusion model, the course of renal failure is
predictable and slowly evolving after a single exposure
to the drug. Using the 129/SV strain of mouse receiving
20 mg/kg cisplatin intraperitoneally, we isolated whole
kidney mRNA from control and cisplatin-exposed ani-
mals one and three days after cisplatin. Hybridization of
cRNA to an Affymetrix HU95A microarray chip was per-
formed and hybridization monitored using Affymetrix
software (Affymetrix; Santa Clara, CA, USA). Differ-
ences in gene expression were analyzed for significance
by two-way analysis of variance (ANOVA). Further anal-
ysis included selection for changes in gene expression
that exceeded control levels by threefold. These genes
were further analyzed by comparing the expression of
these genes to the expression profile of p21 and pre-
pro epidermal growth factor (EGF) with a 99% corre-
lation coefficient because these genes are known to be
up- and down-regulated, respectively, during cisplatin-
and ischemia/reperfusion injury [8, 10]. Only annotated
genes were included in the analysis. This analysis yielded
303 genes. The heat map (Fig. 4) shows that a set of 77
genes increased monotonically from low to high (green
through black to red) after cisplatin, while the remainder
shows depression of gene expression through the obser-
vation period (red-green).
Table 1 summarizes the general findings of this analy-
sis. First, individual genes whose expression was known
to change during cisplatin-induced ARF were also iden-
tified by this approach, and have been classified in broad
categories as before. Thus, changes in gene expression
denoting regeneration, apoptosis, and survival, as well
as those denoting inflammation and cell adhesion were
confirmed. Another theme validated by this approach
involves what appears to be a loss of the mature phe-
notype of the kidney. Many of the genes whose expres-
sion is down-regulated during cisplatin-induced ARF are
those genes that express at high levels only when the kid-
ney achieves full maturity of function. These include the
prepro EGF and Tamm-Horsfall protein genes, whose
functions are unknown in the kidney, but also include
the down-regulation of important membrane transporter
genes, such as aquaporin-2, and sodium proton exchanger
3 (NHE3). The loss of these latter proteins may be respon-
sible, in part, for the tubular reabsorptive defects typical
of this and other forms of ARF.
We interrogated this dataset for changes relevant to
metabolism because it has been proposed that an early
target of cisplatin, as well as ischemia-induced renal fail-
ure, is the mitochondria’s ability to generate ATP. The
mRNA for pyruvate dehydrogenase kinase, which phos-
phorylates and inhibits pyruvate dehydrogenase, a rate-
limiting enzyme for mitochondrial oxidation of pyruvate,
and implies inhibition of aerobic glycolysis. Phospho-
enolpyruvate carboxykinase is markedly up-regulated by
cisplatin, as well, suggesting increased utilization of pyru-
vate to generate glucose, as this enzyme is the key regula-
tor of gluconeogenesis. This notion is further supported
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Fig. 4. Heat map of the changes in mouse
kidney gene expression after cisplatin injec-
tion. Using changes in gene expression of 3-
fold or greater and applying hierarchic clus-
tering, the expression profile of each of these
genes that correlated with the expression pro-
file of preproEGF by 0.99 or greater, and or-
dered by z-score.
Table 1. Molecular responses to renal ischemia
Increased gene expression
Genes involved in cell fate determinations: regeneration,
apoptosis
Transcription factors: c-jun, c-fos
Cyclin dependent kinase inhibitors: p21
Genes involved in inflammation
Chemokines: MCP-1, IL-8
Adhesion molecules: ICAM-1, integrins
Decreased gene expression—loss of mature phenotype
Prepro epidermal growth factor (ppEGF)
Tamm-Horsfall protein
Aquaporin-2
Sodium proton exchanger 3 (NHE3)
Abbreviations are: MCP-1, monocyte chemotactic protein 1; IL-8, interleukin
8; ICAM-1, intercellular adhesion molecule 1.
by the increase in fructose-1,6-biphosphatase, which, like
PEPCK, is a key enzyme in the gluconeogenic pathway.
We are also able to propose that these changes in gene
regulation could be a consequence of cisplatin-induced
acidification, as we found reduced expression of acid ex-
truder and base loader mRNA in our analysis. We have
incorporated these predictions in Figure 5, and are ac-
tively pursuing these predictions both in vivo and vitro
with promising results. We believe that this information
will lead to important new insights into the mechanisms
responsible for ARF.
CONCLUSION
Cell death, survival, and repair are intimately inter-
related after renal injury. The stress response character-
ized by transduction pathways and gene transcription that
serve both positive and negative aspects of cell survival
is intimately involved in the outcome of ischemic and
nephrotoxic damage. The cell cycle and its regulation are
key components of the life and death of the stressed cells
throughout the kidney. Some cells participating in this
response will survive and repair, whereas others will die.
What determines whether a cell will recover from such
injury or undergo cell death by necrosis or apoptosis is
probably a function of the severity of the stress, the spe-
cific changes in gene regulation that the cell is capable of
mounting, and the availability of survival factors in the
cell’s external milieu.
Manipulation of the signal transduction and molecular
pathways provoked by toxic injury may provide an oppor-
tunity in the future to influence ARF (Fig. 6). We have
shown already that up-regulation of the ERK pathway
and down-regulation of JNK improves survival to oxi-
dant stress. Similarly, p21 over-expression protects cells
from ischemic and toxic damage, and may be reasonable
focus of future intervention. Inhibition of cytokine path-
ways also ameliorates ARF, and may do so by bringing a
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Hypothesis: Cisplatin induces intracellular acidification and 
provokes gluconeogenesis and ammoniagenesis
Fig. 5. Predicted impact of cisplatin on renal metabolism of glucose
and intracellular pH.
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Fig. 6. Survival factors may influence the signal transduction and tran-
scriptional programs initiated by stress. The balance between the pro-
survival or prodeath aspects of the stress response determines the ulti-
mate fate of the cells. Both the cyclin-kinase inhibitor p21 protein and
extracellular-regulated kinase (ERK) protect renal cells from oxidant
injury.
more positive balance in these pathways promoting sur-
vival. We propose that intervening in the metabolic conse-
quences of the molecular response, such as the inhibition
of pyruvate oxidation, may also be amenable to manip-
ulation. Additional targets will almost certainly be pro-
vided by the application and analysis of high-throughput
gene expression and proteomics just now being applied
to this interesting and pertinent field of study.
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